Marketdash
Back to Stock Market News

Biotech's Six-Month Asthma Shot Shows Promising Trial Results

MarketDash Editorial Team
2 days ago
Apogee Therapeutics unveiled encouraging Phase 1b data for its asthma treatment APG777, showing sustained reduction in inflammation markers for up to 32 weeks after a single dose with no safety concerns.

Apogee Therapeutics Inc. (APGE) delivered some interesting news Tuesday about its experimental asthma drug, and the headline is pretty compelling: one shot that could control inflammation for up to six months.

The biotech company released interim Phase 1b trial data for zumilokibart (APG777) covering 19 adults with mild-to-moderate asthma. Researchers focused on fractional exhaled nitric oxide, or FeNO, which is basically a key marker that tells you how much Type 2 inflammation is happening in someone's airways. Higher FeNO levels correlate strongly with asthma exacerbations, so driving this number down matters.

The Numbers That Matter

Here's what APG777 accomplished after a single dose: The drug delivered a maximum absolute mean FeNO reduction of 45 ppb, representing a 60% drop from baseline levels. That's substantial.

But the durability might be even more impressive. Every patient maintained FeNO suppression through 16 weeks. For those with longer follow-up data available, the suppression lasted through 32 weeks. This kind of staying power opens the door for dosing schedules of once every three or even six months, which would be a real convenience factor for patients.

The trial also showed positive trends in forced expiratory volume in one second (FEV1), a pharmacodynamic measure that tracks lung function, along with improvements across other Type 2 inflammation biomarkers.

Safety Profile Looks Clean

APG777 was well-tolerated across the board. Notably, researchers observed zero cases of conjunctivitis, no injection site reactions, and no anti-drug antibodies developed. That's a clean safety readout for this stage.

What's Next

Apogee has mapped out an aggressive 2026 timeline. The company expects Phase 2 APEX Part A maintenance data (52-week study) in Q1 2026, followed by Phase 2 APEX Part B induction data (16-week study) in Q2 2026.

The big milestone comes in the second half of 2026 when Apogee plans to kick off Phase 3 trials, which could position the drug for a potential 2029 launch if everything goes smoothly.

The company also has a head-to-head trial comparing APG279 (a combination of APG777 and APG990) against Dupixent for moderate-to-severe atopic dermatitis, with results expected in the second half of 2026.

As of September 30, 2025, Apogee reported $913 million in cash, providing runway into the second half of 2028.

Apogee shares dropped 2.84% to $75.00 on Tuesday following the announcement.

Back to Stock Market News

Biotech's Six-Month Asthma Shot Shows Promising Trial Results

MarketDash Editorial Team
2 days ago
Apogee Therapeutics unveiled encouraging Phase 1b data for its asthma treatment APG777, showing sustained reduction in inflammation markers for up to 32 weeks after a single dose with no safety concerns.

Apogee Therapeutics Inc. (APGE) delivered some interesting news Tuesday about its experimental asthma drug, and the headline is pretty compelling: one shot that could control inflammation for up to six months.

The biotech company released interim Phase 1b trial data for zumilokibart (APG777) covering 19 adults with mild-to-moderate asthma. Researchers focused on fractional exhaled nitric oxide, or FeNO, which is basically a key marker that tells you how much Type 2 inflammation is happening in someone's airways. Higher FeNO levels correlate strongly with asthma exacerbations, so driving this number down matters.

The Numbers That Matter

Here's what APG777 accomplished after a single dose: The drug delivered a maximum absolute mean FeNO reduction of 45 ppb, representing a 60% drop from baseline levels. That's substantial.

But the durability might be even more impressive. Every patient maintained FeNO suppression through 16 weeks. For those with longer follow-up data available, the suppression lasted through 32 weeks. This kind of staying power opens the door for dosing schedules of once every three or even six months, which would be a real convenience factor for patients.

The trial also showed positive trends in forced expiratory volume in one second (FEV1), a pharmacodynamic measure that tracks lung function, along with improvements across other Type 2 inflammation biomarkers.

Safety Profile Looks Clean

APG777 was well-tolerated across the board. Notably, researchers observed zero cases of conjunctivitis, no injection site reactions, and no anti-drug antibodies developed. That's a clean safety readout for this stage.

What's Next

Apogee has mapped out an aggressive 2026 timeline. The company expects Phase 2 APEX Part A maintenance data (52-week study) in Q1 2026, followed by Phase 2 APEX Part B induction data (16-week study) in Q2 2026.

The big milestone comes in the second half of 2026 when Apogee plans to kick off Phase 3 trials, which could position the drug for a potential 2029 launch if everything goes smoothly.

The company also has a head-to-head trial comparing APG279 (a combination of APG777 and APG990) against Dupixent for moderate-to-severe atopic dermatitis, with results expected in the second half of 2026.

As of September 30, 2025, Apogee reported $913 million in cash, providing runway into the second half of 2028.

Apogee shares dropped 2.84% to $75.00 on Tuesday following the announcement.